FIELD: organic chemistry.
SUBSTANCE: present invention relates to a compound of formula I.1:
or a stereoisomer thereof, where radicals are defined in the claim. Also disclosed is a method of inhibiting the biological activity of cyclin-dependent protein kinases CDK8/19, a pharmaceutical composition, method of treating a disease or disorder, using the compound for treating a disease or disorder.
EFFECT: invention discloses novel organic compounds having CDK8/19 inhibitor properties suitable for treating an oncological or haemato-oncological disease.
16 cl, 7 tbl, 135 ex
Title | Year | Author | Number |
---|---|---|---|
NEW CDK8/19 INHIBITORS | 2018 |
|
RU2763347C2 |
CDK8/19 INHIBITORS | 2018 |
|
RU2761824C2 |
NEW CDK8/19 INHIBITORS | 2019 |
|
RU2754441C2 |
INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2018 |
|
RU2786524C2 |
INHIBITORS OF FACTOR VIIA | 2000 |
|
RU2248359C2 |
EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | 2022 |
|
RU2821531C2 |
ALLOSTERIC MODULATORS OF METABOLIC GLUTAMATE RECEPTORS | 2004 |
|
RU2360902C2 |
BENZYLPHENYLCYCLOHEXANE DERIVATIVES AND METHODS OF THEREOF APPLICATION | 2008 |
|
RU2505521C2 |
PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE-3-KINASE INHIBITORS | 2015 |
|
RU2695374C2 |
DERIVATIVES OF BIPIPERIDINE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2296751C2 |
Authors
Dates
2020-12-24—Published
2018-03-06—Filed